Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1684/ejd.2013.2043 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Through thick and thin: confronting the aggressive cutaneous T-cell lymphomas.
Hematology Am Soc Hematol Educ Program
December 2024
Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
The cutaneous T-cell lymphomas (CTCLs) comprise a diverse set of diseases with equally diverse presentations ranging from asymptomatic solitary lesions to highly aggressive diseases with propensity for visceral spread. The more aggressive CTCLs, which herein we consider as certain cases of advanced-stage mycosis fungoides/Sézary syndrome (MF/SS), primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma (PCAETCL), and primary cutaneous gamma delta T-cell lymphoma (PCGDTCL), require systemic therapy. Over the last 5 years, treatment options for MF/SS have expanded with biological insights leading to new therapeutic options and increasingly unique management strategies.
View Article and Find Full Text PDFPrimary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder: a case report and literature review.
Acta Dermatovenerol Alp Pannonica Adriat
November 2024
Institute of Pathology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder (PCSM-LPD) is characterized by a slow-growing and asymptomatic solitary plaque or tumor, usually involving the head, neck, or upper extremities. The diagnosis is established based on clinical presentation, histopathological features including pleomorphic morphology and CD4-positive immunophenotype of neoplastic T lymphocytes, and molecular analysis showing clonally rearranged T-cell receptor (TCR) genes. Plaques typical of mycosis fungoides are essentially absent.
View Article and Find Full Text PDFEvaluation of different standard and modified two-tier testing strategies for the laboratory diagnosis of lyme borreliosis in a European setting.
Eur J Clin Microbiol Infect Dis
December 2024
Department of Medical Microbiology and Immunology, Diakonessenhuis Hospital, Utrecht, The Netherlands.
Article Synopsis
- The study looked at different testing methods for diagnosing Lyme disease, focusing on two strategies: standard (STTT) and modified (MTTT).
- Both testing strategies were used on patients with Lyme neuroborreliosis (LNB) and Lyme arthritis (LA) to see how well they worked.
- The results showed that the modified strategy was slightly better in finding Lyme disease without losing accuracy, making it a good choice for doctors to use.
Immunological Tumor Microenvironment of Solitary Fibrous Tumors-Associating Immune Infiltrate with Variables of Prognostic Significance.
Cancers (Basel)
September 2024
Pathology Department, University of Valencia, 46010 Valencia, Spain.
Article Synopsis
- * A study of 52 confirmed SFT cases used immunohistochemical analysis of various markers to investigate their correlation with patient outcomes and existing risk stratification systems.
- * Results indicated that immune cell presence didn't significantly impact prognosis, but one case with high immune infiltrate showed progression; certain immune markers revealed associations with tumor characteristics and behaviors, suggesting complex interactions in the tumor microenvironment.
Dendritic Cell-Based Immunotherapy in Patients With Resected Pancreatic Cancer.
J Clin Oncol
September 2024
Department of Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
Purpose: Immunotherapies have shown limited responses in patients with advanced pancreatic cancer. Recently, we reported that dendritic cell (DC)-based immunotherapy induced T-cell responses against pancreatic cancer antigens. The primary objective of this study was to determine the efficacy of DC-based immunotherapy to prevent recurrence of disease.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!